Success Metrics

Active Trials

5(100%)

Phase Distribution

Ph phase_1

60%

Ph phase_3

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

3(60.0%)

Phase 3Large-scale testing

2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Detailed Status

Recruiting4

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 13 (60.0%)

Phase 32 (40.0%)

Trials by Status

active_not_recruiting120%

recruiting480%

Recent Activity

5 active trials

Showing 5 of 5

recruitingphase_3

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

NCT07085767

recruitingphase_3

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT06016738

active_not_recruitingphase_1

A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

NCT05266105

recruitingphase_1

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

NCT05508906

recruitingphase_1

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

NCT06784193

Clinical Trials (5)

Showing 5 of 5 trials

NCT07085767Phase 3

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Recruiting

NCT06016738Phase 3

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Recruiting

NCT05266105Phase 1

A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

Active Not Recruiting

NCT05508906Phase 1

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Recruiting

NCT06784193Phase 1

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Recruiting

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5